Neurogene reports preclinical gene-expression findings for Rett therapy NGN-401
Neurogene reported rapid, durable gene expression in a preclinical study of its Rett therapy NGN-401.
Related stories
Oracle Shares Fall Over 3% as Company Sets $20 Billion Financing Ceiling
Oracle said it is capping additional fundraising at $20 billion as investors scrutinize the cash demands of its AI expansion. Shares traded at $140.14 on October 29, down approxima
M impact | EQUITY | Oct 29, 2026, 06:06 PM UTC
Nvidia Shares Fall 0.77% to $213.73 in Morning Trading
Nvidia shares were down 0.77% at $213.73 at 10:20 a.m. ET on October 29. The report says Oracle’s infrastructure rollout highlights an opportunity for Vera CPUs in AI workloads.
M impact | EQUITY | Oct 29, 2026, 06:06 PM UTC
Dynamix to Liquidate After Failing to Complete Business Combination
Dynamix Corp. said it could not complete a business combination by its deadline and will liquidate. It expects to redeem public shares for about $10.71 each; Thursday is expected t
L impact | EQUITY | Oct 29, 2026, 06:05 PM UTC
Analysts Raise Price Targets for Axogen After Q3 Results
Truist and Barclays lifted Axogen price targets to $60, from $53 and $50, respectively; Wells Fargo raised its target to $56 from $48. Truist and Barclays maintained Buy ratings.
M impact | EQUITY | Oct 29, 2026, 06:03 PM UTC
Darling Ingredients Reports Q3 2026 Adjusted EBITDA of $514 Million
Darling Ingredients reported Q3 2026 net income of $267 million, reduced net debt by $420 million during the period and reaffirmed full-year 2026 EBITDA guidance of $2.2 billion to
M impact | EQUITY | Oct 29, 2026, 06:03 PM UTC
Bunge Reports Third-Quarter 2026 Revenue of $23.8 Billion, EPS
Bunge reported GAAP diluted EPS of $1.64, versus $0.86 a year earlier, and adjusted EPS of $2.56, versus $2.27. It reiterated full-year adjusted EPS guidance of $9.25 to $9.75.
M impact | EQUITY | Oct 29, 2026, 06:03 PM UTC